$CD33^{-}CD16^{+}$ NK cells (lower right side panel). These cell populations were analysed for HLA-DR (vertical axis) and GPI-80 (horizontal axis) expression.

3) In the reference 9, Solito et al. showed six types of MDSCs in these RCC patients. If authors had studied this kind of patients, those types of MDSCs could have analyzed to validate GPI-80 expression.

According to the reviewer's suggestion, we summarized the association between the previously used marker and GPI-80 expression as follows (please see the results section, pp 24, line 18~pp 25, line 3, and supplemental Table 1):

Based on these observations, we summarized the association between reported MDSC markers and GPI-80 expression in Suppl. Table 1. The observations of GPI-80 CV in $CD16^{hi}$ and GPI-80 MFI in $CD33^{hi}$ populations were applied to all reported MDSC subsets.

Suppl. Table 1. Association between reported MDSC markers and GPI-80 expression.

Reported MDSC markers	Related population	GPI-80 expression
$CD14^{+}IL\text{-}4R\alpha^{+}$	$CD33^{hi}$	$GPI\text{-}80^{+}$*
$CD33^{+}HLA\text{-}DR^{-}$	$CD33^{hi}$ and $CD16^{hi}$	$GPI\text{-}80^{+}$* and $GPI\text{-}80^{++}$**
$CD11b^{+}CD14^{+}CD33^{+}$	$CD33^{hi}$	$GPI\text{-}80^{+}$*
$CD33^{+}HLA\text{-}DR^{-}CD15^{+}$	$CD16^{hi}$	$GPI\text{-}80^{++}$**
$CD15^{+}IL\text{-}4R\alpha^{+}$	$CD16^{hi}$	$GPI\text{-}80^{++}$**
$CD11b^{+}CD15^{+}CD66b^{+}$	$CD16^{hi}$	$GPI\text{-}80^{++}$**
$CD11b^{+}CD14^{-}CD15^{+}$	$CD16^{hi}$	$GPI\text{-}80^{++}$**
$CD15^{+}CFCS^{lo}SSC^{hi}$	$CD16^{hi}$	$GPI\text{-}80^{++}$**
$CD11c^{bright}CD62L^{dim}CD11b^{bright}CD16^{bright}$	$CD16^{hi}$	$GPI\text{-}80^{++}$**

*MFI of $GPI\text{-}80^{+}$ (intermediate) cells, which increases during the appearance of MDSCs, indicates an increase in ROS production and potency.

**CV of $GPI\text{-}80^{++}$ (high) cells, which increases during the appearance of MDSCs, suggests increasing the capability to suppress T cell proliferation.


Day 0
Day 4
CD71
CD11b
CD16
CD11b
CD16
GPI-80
Q1 76.4%
Q2 0.607%
Q4 17.9%
Q3 5.08%
Q1 21.7%
Q2 3.58%
Q4 18.7%
Q3 56.1%
Q1 1.82%
Q2 3.22%
Q4 93.5%
Q3 1.44%
Q1 1.23%
Q2 38.4%
(c)
(a)
(b)
Q4 39.2%
Q3 21.2%
Q1 3.36%
Q2 0.683%
Q4 95.9%
Q3 0.085%
Q1 24.0%
Q2 15.9%
(e)
(f)
(d)
Q4 58.5%
Q3 1.64%


(a)
(b)
(c)
(d)
(e)
(f)

Suppl. Fig.1


(a)
vehicle
+G-CSF
0 min
30 min
GPI-80
BipParticle
GPI-80⁺ subset
(b)
G-CSF
GM-CSF
BioParticle (MFI)
0 min
30 min
vehicle
+G-CSF
+G-CSF +IL-6
+GM-CSF
+GM-CSF +IL-6
NS
(c)
OD595 nm
fMLP (-)
fMLP (+)
(d)
CellROX (MFI)
GPI-80(-)
GPI-80(+)

Suppl. Fig.2


(a)
12.6%
21.6%
vehicle
48.2%
17.6%
1.92%
32.1%
G-CSF
25.6%
40.3%
0.268%
8.29%
GM-CSF
43.6%
47.8%
0.396%
12.2%
G-CSF +
GM-CSF
28.2%
59.2%
GPI-80
CD14
0
10^2
10^3
10^4
10^5

Suppl. Fig. 3a


(b)
vehicle
0.226%
1.02%
59.5%
39.2%
G-CSF
0.048%
0.834%
26.6%
72.5%
GM-CSF
0.069%
0.960%
42.1%
56.9%
G-CSF +
GM-CSF
0.028%
1.04%
27.5%
71.4%
HLA-DR
CD14
0
10^2
10^3
10^4
10^5

Suppl. Fig. 3b


(c)
vehicle
36.2%
0.438%
63.2%
0.258%
G-CSF
33.0%
2.68%
62.7%
1.70%
GM-CSF
8.65%
1.31%
88.7%
1.29%
G-CSF +
GM-CSF
8.37%
4.81%
80.1%
6.73%
GPI-80
CD64
0
10^2
10^3
10^4
10^5

Suppl. Fig. 3c


CD33
CD16
CD15
5.86%
1.78%
48.2%
42.9%
5.57%
2.11%
47.6%
44.1%
CD33hi
CD16hi
or CD15hi
CD11b
relative count
GPI-80-FITC
GPI-80-PE

Suppl. Fig. 4


CD33
CD16
Lymphocytes
CD16+ NK cells
HLA-DR
GPI-80
13.5%
1.41%
80.8%
4.30%
8.19%
0.809%
85.4%
5.58%

Suppl. Fig. 5


CD33hi monocytic cells
p = 0.008
patients
volunteers
(x10³)
3
2
1
0
GPI-80 MFI
0
2
4
6
(x10²)
CD16 MFI

Suppl. Fig. 6